Dolutegravir: A Next-Generation Integrase Inhibitor for Treatment of HIV Infection
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Dolutegravir: A Next-Generation Integrase Inhibitor for Treatment of HIV Infection
Authors
Keywords
-
Journal
CLINICAL INFECTIOUS DISEASES
Volume 59, Issue 2, Pages 265-271
Publisher
Oxford University Press (OUP)
Online
2014-04-11
DOI
10.1093/cid/ciu221
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Dolutegravir in antiretroviral-naive adults with HIV-1
- (2013) Hans-Jürgen Stellbrink et al. AIDS
- Effect of Prednisone on the Pharmacokinetics of the Integrase Inhibitor Dolutegravir
- (2013) Ivy H. Song et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Metabolism, Excretion, and Mass Balance of the HIV-1 Integrase Inhibitor Dolutegravir in Humans
- (2013) Stephen Castellino et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Lack of Pharmacokinetic Interaction between Rilpivirine and Integrase Inhibitors Dolutegravir and GSK1265744
- (2013) Susan L. Ford et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Dolutegravir does not affect methadone pharmacokinetics in opioid-dependent, HIV-seronegative subjects
- (2013) Ivy Song et al. DRUG AND ALCOHOL DEPENDENCE
- Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment
- (2013) Stephen Weller et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study
- (2013) Pedro Cahn et al. LANCET
- Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study
- (2013) Francois Raffi et al. LANCET
- Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial
- (2013) François Raffi et al. LANCET INFECTIOUS DISEASES
- Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials
- (2013) Joseph J Eron et al. LANCET INFECTIOUS DISEASES
- Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection
- (2013) Sharon L. Walmsley et al. NEW ENGLAND JOURNAL OF MEDICINE
- A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects
- (2012) Justin Koteff et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Safety, Tolerability, and Pharmacokinetics of the HIV Integrase Inhibitor Dolutegravir Given Twice Daily With Rifampin or Once Daily With Rifabutin
- (2012) Kelly E. Dooley et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study
- (2012) Joseph J. Eron et al. JOURNAL OF INFECTIOUS DISEASES
- Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks
- (2012) Paul E Sax et al. LANCET
- Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial
- (2012) Edwin DeJesus et al. LANCET
- Effects of Etravirine Alone and with Ritonavir-Boosted Protease Inhibitors on the Pharmacokinetics of Dolutegravir
- (2011) Ivy Song et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Effect of Food on the Pharmacokinetics of the Integrase Inhibitor Dolutegravir
- (2011) Ivy Song et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next-generation HIV integrase inhibitor, S/GSK1349572
- (2011) Ivy Song et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Long-term Treatment With Raltegravir or Efavirenz Combined With Tenofovir/Emtricitabine for Treatment-Naive Human Immunodeficiency Virus-1–Infected Patients: 156-Week Results From STARTMRK
- (2011) Jürgen K. Rockstroh et al. CLINICAL INFECTIOUS DISEASES
- Pharmacokinetics of the HIV integrase inhibitor S/GSK1349572 co-administered with acid-reducing agents and multivitamins in healthy volunteers
- (2011) P. Patel et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial
- (2011) Jan van Lunzen et al. LANCET INFECTIOUS DISEASES
- Structural and Functional Analyses of the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir (S/GSK1349572)
- (2011) S. Hare et al. MOLECULAR PHARMACOLOGY
- In VitroAntiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor
- (2010) Masanori Kobayashi et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Lack of Interaction Between the HIV Integrase Inhibitor S/GSK1349572 and Tenofovir in Healthy Subjects
- (2010) Ivy Song et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens
- (2010) D. da Silva et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- The Effect of Lopinavir/Ritonavir and Darunavir/Ritonavir on the HIV Integrase Inhibitor S/GSK1349572 in Healthy Participants
- (2010) Ivy Song et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Pharmacokinetics and Safety of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor, in Healthy Volunteers
- (2009) S. Min et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Life Expectancy After HIV Diagnosis Based on National HIV Surveillance Data From 25 States, United States
- (2009) Kathleen McDavid Harrison et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Comparison of Raltegravir and Elvitegravir on HIV-1 Integrase Catalytic Reactions and on a Series of Drug-Resistant Integrase Mutants†
- (2008) Jessica Marinello et al. BIOCHEMISTRY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started